RESUMO
A double blind comparative study was conducted to evaluate the efficacy and safety of penfluridol and trifluoperazine in patients of chronic schizophrenia. Penfluridol was administered once weekly while trifluoperazine was administered twice daily by preparing identical capsules. The data revealed that both the compounds were similarly effective in maintaining control of symptoms of chronic schizophrenia. However, penfluridol has a definite advantage over trifluoperazine since it is administered once a week instead of twice a day.
Assuntos
Penfluridol/uso terapêutico , Piperidinas/uso terapêutico , Esquizofrenia/tratamento farmacológico , Trifluoperazina/uso terapêutico , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Esquema de Medicação , Fadiga/induzido quimicamente , Feminino , Humanos , Masculino , Penfluridol/administração & dosagem , Penfluridol/efeitos adversos , Distribuição Aleatória , Psicologia do Esquizofrênico , Distúrbios do Início e da Manutenção do Sono/induzido quimicamente , Trifluoperazina/administração & dosagem , Trifluoperazina/efeitos adversosRESUMO
A double blind therapeutic comparison of single dose administration of imipramine pamoate and divided dose of imipramine hydrochloride was made in 40 indoor patients suffering from depressive illness. A fixed dose of 150 mg was used for both drugs for four weeks, employing randomized methodology with placebo capsules and tablets to balance dosage schedules. Four patients two from each group were dropped, leaving 36 patients for final analysis. The criteria of assessment were Hamilton Rating Scale and global evaluation by both the psychiatrist and the patients. Both the dosage forms were found to be highly effective as anti-depressants. Imipramine pamoate seemed to provide more consistent improvement but statistically the differences were not significant at the end of four weeks treatment. The major conclusion drawn from the study was the confirmation of therapeutic equivalence between a single daily dose of 150 mg of imipramine pamoate and divided dose of 150 mg of imipramine hydrochloride. Generally mild side-effects occurred with equal frequency in both the groups and no adverse effects on haemopoietic, renal or hepatic function were seen with either dosage form.
Assuntos
Transtorno Depressivo/tratamento farmacológico , Imipramina/administração & dosagem , Adolescente , Adulto , Idoso , Antidepressivos/efeitos adversos , Ensaios Clínicos como Assunto , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Imipramina/efeitos adversos , Imipramina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Cooperação do PacienteRESUMO
The therapeutic results obtained with Nitrazepam in 30 children with emotional disorders between 4 and 14 years of age are reported, 17 children with habit disorders, 6 with behaviour, 5 with personality and 2 with Neurosis. Employing a flexible dosage schedule, a dose of 1/4 tablet to 1 tablet of 5 mg. Nitrazepam once to thrice daily was effective and safe. 24 of the 30 children (80%) showed recovery or marked improvement with over 50% fall in percentage reduction in total score based on assessing the target symptoms.